Screener
Recursion Pharmaceuticals, Inc. RXRX Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Other receivables and assets | 8,454 | 30,246 |
| Prepaid data assets | 3,062 | 29,601 |
| Accrued data liability | — | 20,258 |
| Unearned revenue | (9,552) | (23,383) |
| Accounts payable | (5,602) | (1,145) |
| Accrued development expense | (814) | (155) |
| Accrued expenses and other current liabilities | (12,623) | (15,213) |
| Lease liabilities | (9,290) | (10,908) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported increase (decrease) in contract liabilities and current deferred income of -$7.3M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income increased by 46.4% year-over-year, from -$13.62M to -$7.3M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 2 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a 91.8% compound annual growth rate (CAGR), from -$10M to -$36.77M.
- What does increase (decrease) in contract liabilities and current deferred income mean?
- Increase (decrease) in contract liabilities and current deferred income
Ask your AI about Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude